Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome

Human Molecular Genetics

Volumn 19, Issue 24, 2010, Pages 4790-4798

  Nistala, Harikiran ^a   Lee Arteaga, Sui ^a   Carta, Luca ^a   Cook, Jason R ^a   Smaldone, Silvia ^a   Siciliano, Gabriella ^a   Rifkin, Aaron N ^a,b   Dietz, Harry C ^c   Rifkin, Daniel B ^b   Ramirez, Francesco ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; LOSARTAN; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ANEURYSM; AORTA WALL; ARTICLE; CELL DIFFERENTIATION; MARFAN SYNDROME; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; UPREGULATION; VASCULAR DISEASE; WILD TYPE;

ALENDRONATE; ANIMALS; AORTA; AORTIC ANEURYSM; BONE DISEASES, METABOLIC; BONE MORPHOGENETIC PROTEINS; BONE RESORPTION; DISEASE MODELS, ANIMAL; LOSARTAN; MARFAN SYNDROME; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MUTATION; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; SPINE; TOMOGRAPHY, X-RAY COMPUTED; TRANSFORMING GROWTH FACTOR BETA;

MUS;

EID: 78649472965     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq409     Document Type: Article

References (50)

1. Ramirez, F. and Dietz, H.C. (2007) Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr. Opin. Genet. Dev., 17, 252-258.
2. Neptune, E.R., Frischmeyer, P.A., Arking, D.E., Myers, L., Bunton, T.E., Gayraud, B., Ramirez, F., Sakai, L.Y. and Dietz, H.C. (2003) Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat. Genet., 33, 407-411.
3. Ng, C.M., Cheng, A., Myers, L.A., Martinez-Murillo, F., Jie, C., Bedja, D., Gabrielson, K.L., Hausladen, J.M., Mecham, R.P., Judge, D.P. et al. (2004) TGF-b activation contributes to pathogenesis of mitral valve prolapsed in a mouse model of Marfan syndrome. J. Clin. Invest., 114, 1586-1592.
4. Habashi, J.P., Judge, D.P., Holm, T.M., Cohn, R.D., Loeys, B.L., Cooper, T.K., Myers, L., Klein, E.C., Liu, G., Calvi, C. et al. (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 312, 117-121.
5. Cohn, R.D., van Erp, C., Habashi, J.P., Loeys, B.L., Klein, E.C., Holm, T.M., Judge, D.P., Ramirez, F. and Dietz, H.C. (2007) Angiotensin II type 1 receptor blockade attenuates TGFb induced failure of muscle regeneration in multiple myopathic states. Nat. Med., 13, 204-210.
6. Lim, D.-S., Lutucuta, S., Bachireddy, P., Youker, K., Evans, A., Entman, M., Roberts, R. and Marian, A.J. (2001) Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation, 103, 789-791.
7. Lavoie, P., Robitaille, G., Agharazii, M., Ledbetter, S., Lebel, M. and Lariviere, R. (2005) Neutralization of transforming growth factor-b attenuates hypertension and prevents renal injury in uremic rats. Hypertens., 23, 1895-1903.
8. Brooke, B.S., Habashi, J.P., Judge, D., Patel, N., Loeys, B. and Dietz, H.C. (2008) Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N. Engl. J. Med., 358, 2787-2795.
9. Miller, J.A., Thai, K. and Scholey, J.W. (1999) Angiotensin II receptor type I gene polymorphism predicts response to losartan and angiotensin II. Kidney Int., 56, 2173-2180.
10. Arsenault, J., Lehoux, J., Lanthier, L., Cabana, J., Guillemette, G., Lavigne, P., Leduc, R. and Escher, E. (2010) A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity. Pharmacogenet. Genomics, 20, 377-388.
11. Giampietro, P.F., Raggio, C. and Davis, J.G. (2002) Marfan syndrome: orthopedic and genetic review. Curr. Opin. Pediatr., 14, 35-41.
12. Gray, J.R., Bridges, A.B., Moie, P.A., Pringle, T., Boxer, M. and Paterson, C.R. (1993) Osteoporosis and the Marfan syndrome. Postgrad. Med. J., 69, 373-375.
13. Kohlmeier, L., Gasner, C. and Marcus, R. (1993) Bone mineral status of women with Marfan syndrome. Am. J. Med., 95, 568-572.
14. Kohlmeier, L., Gasner, C., Bachrach, L.K. and Marcus, R. (1995) The bone mineral status of patients with Marfan syndrome. J. Bone Min. Res., 10, 1550-1555.
15. Tobias, J.H., Dalzell, N. and Child, A.H. (1995) Assessment of bone mineral density in women with Marfan syndrome. Br. J. Rheumatol., 34, 516-519.
16. Le Parc, J.M., Plantin, P., Jondeau, G., Goldschild, M., Albert, M. and Boileau, C. (1999) Bone mineral density in sixty adult patients with Marfan syndrome. Osteoporos. Int., 10, 475-479.
17. Carter, N., Duncan, E. and Wordsworth, P. (2000) Bone mineral density in adults with Marfan syndrome. Rheumatology (Oxford), 39, 307-309.
18. Giampietro, P.F., Peterson, M., Schneider, R., Davis, J.G., Raggio, C., Myers, E., Burke, S.W., Boachie-Adjei, O. and Mueller, C.M. (2003) Assessment of bone mineral density in adults and children with Marfan syndrome. Osteoporos. Int., 14, 559-563.
19. Moura, B., Tubach, F., Sulpice, M., Boileau, C., Jondeau, G., Muti, C., Chevallier, B., Ounnoughene, Y. and Le Parc, J.M. (2006) Bone mineral density in Marfan syndrome. A large case-control study. Joint Bone Spine, 73, 733-735.
20. Giampietro, P.F., Peterson, M.G., Schneider, R., Davis, J.G., Burke, S.W., Boachie-Adjei, O., Mueller, C.M. and Raggio, C.L. (2007) Bone mineral density determinations by dual-energy X-ray absorptiometry in the management of patients with Marfan syndrome-some factors which affect the measurement. HSS J., 3, 89-92.
21. Barisic-Dujmovic, T., Boban, I., Adams, D.J. and Clark, S.H. (2007) Marfan-like skeletal phenotype in the tight skin (Tsk) mouse. Calcif. Tissue Int., 81, 305-315.
22. Nistala, H., Lee-Arteaga, S., Smaldone, S., Siciliano, G., Carta, L., Ono, R., Sengle, G., Arteaga-Solis, E., Levasseur, R., Ducy, P. et al. (2010) Fibrillin-1 and -2 differentially modulate endogenous TGFb and BMP bioavailability during bone formation. J. Cell Biol., 190, 1107-1121.
23. Nistala, H., Lee-Arteaga, S., Smaldone, S., Siciliano, G. and Ramirez, F. (2010) Extracellular microfibrils control osteoblast-supported osteoclastogenesis by restricting TGFβ stimulation of RANKL production. J. Biol. Chem., 21 August 2010 [Epub ahead of print].
24. Siracusa, L.D., McGrath, R., Ma, Q., Moskow, J.J., Manne, J., Christner, P.J., Buchberg, A.M. and Jimenez, S.A. (1996) A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res., 6, 300-313.
25. Kielty, C., Rughunath, M., Siracusa, L.D., Sherratt, J.J., Peters, R., Shuttleworth, C.A. and Jimenez, S.A. (1998) The tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils. J. Cell Biol., 140, 1159-1166.
26. Gayraud, B., Keene, D.R., Sakai, L.Y. and Ramirez, F. (2000) New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin-1 mutation in the tight skin mouse. J. Cell Biol., 150, 667-680.
27. Loeys, B.L., Gerber, E.E., Riegert-Johnson, D., Iqbal, S., Whiteman, P., McConnell, V., Chillakuri, C.R., Macaya, D., Coucke, P.J., De Paepe, A. et al. (2010) Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci. Transl. Med., 2, 23ra20.
28. Carta, L., Pereira, L., Arteaga-Solis, E., Lee-Arteaga, S.Y., Lenart, B., Starcher, B., Merkel, C.A., Sukoyan, M., Kerkis, A., Hazeki, N. et al. (2006) Fibrillins 1 and 2 perform partially overlapping functions during aortic development. J. Biol. Chem., 281, 8016-8023.
29. Pereira, L., Lee, S.Y., Gayraud, B., Andrikopoulos, K., Shapiro, S.D., Bunton, T., Jensen Biery, N., Dietz, H.C., Sakai, L.Y. and Ramirez, F. (1999) Pathogenetic sequence for aneurysm revealed in mice fibrillin 1. Proc. Natl Acad. Sci. USA, 96, 3819-3823.
30. Kalajzic, I., Staal, A., Yang, W.P., Wu, Y., Johnson, S.E., Feyen, J.H., Krueger, W., Maye, P., Yu, F., Zhao, Y. et al. (2005) Expression profile of osteoblast lineage at defined stages of differentiation. J. Biol. Chem., 280, 24618-24626.
31. Bi, Y., Nielsen, K.L., Kilts, T.M., Yoon, A., Karsdal, A.M., Wimer, H.F., Greenfield, E.M., Heegaard, A.M. and Young, M.F. (2006) Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts. Bone, 38, 778-786.
32. Teitelbaum, S.L. (2000) Bone resorption by osteoclasts. Science, 289, 1504-1508.
33. Reszka, A.A. and Rodan, G.A. (2003) Mechanism of action of bisphosphonates. Curr. Osteopor. Res., 1, 45-52.
34. Touyz, R.M., He, G., El Mabrouk, M. and Schiffrin, E.L. (2001) p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension, 37, 574-580.
35. Shimizu, H., Nakagami, H., Osako, M.K., Hanayama, R., Kunugiza, Y., Kizawa, T., Tomita, T., Yoshikawa, H., Ogihara, T. and Morishita, R. (2008) Antiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J., 22, 2465-2475.
36. Maeda, S., Hayashi, M., Komiya, S., Imamura, T. and Miyazono, K. (2004) Endogenous TGFb signaling suppresses maturation of osteoblastic mesenchymal cell. EMBO J., 23, 552-563.
37. Alliston, T., Piek, E. and Derynck, R. (2008) TGF-b family signaling in skeletal development, maintenance and disease. In Derynck, R. and Miyazono, K. (eds), The TGFβ Family, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 667-723.
38. Rodriguez-Vita, J., Sanchez-Lopez, E., Esteban, V., Ruperez, M., Egido, J. and Ruiz-Ortega, M. (2005) Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-β-independent mechanism. Circulation, 111, 2509-2417.
39. Yang, F., Chung, A.C., Huang, X.R. and Lan, H.Y. (2009) Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-β-dependent and -independent Smad pathways: the role of Smad3. Hypertension, 54, 877-884.
40. Zou, Y., Akazawa, H., Qin, Y., Sano, M,, Takano, H., Minamino, T., Makita, N., Iwanaga, K., Zhu, W., Kudoh, S. et al. (2004) Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat. Cell Biol., 6, 499-506.
41. Rakesh, K., Yoo, B., Kim, I.M., Salazar, N., Kim, K.S. and Rockman, H.A. (2010) β-arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci. Signal., 3, ra46.
42. Lynn, H., Kwok, T., Wong, S.Y., Woo, J. and Leung, P.C. (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone, 38, 584-588.
43. Shimizu, H., Nakagami, H., Osako, M.K., Nakagami, F., Kunugiza, Y., Tomita, T., Yoshikawaka, H., Rakugi, H., Ogihara, T. and Morishita, R. (2009) Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens. Res, 32, 786-790.
44. Broulik, P.D., Tesar, V., Zima, T. and Jirsa, M. (2001) Impact of antihypertensive therapy on the skeleton: effects of enalapril and AT1 receptor antagonist losartan in female rats. Physiol. Res., 50, 355-358.
45. Izu, Y., Mizoguchi, F., Kawamata, A., Hayata, T., Nakamoto, T., Nakashima, K., Inagami, T., Ezura, Y. and Noda, M. (2009) Angiotensin II type 2 receptor blockade increases bone mass. J. Biol. Chem., 284, 4857-4864.
46. Li, Y.Q., Ji, H., Shen, Y., Ding, L.J., Zhuang, P., Yang, Y.L. and Huang, Q.J. (2009) Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGFβ1 levels in ovariectomized rats. Can. J. Physiol. Pharmacol., 87, 51-55.
47. Konstam, M.A., Neaton, J.D., Dickstein, H., Drexel, H., Komajada, M., Martinez, F.A., Riegger, G.A.J., Malbecq, W., Smith, R.D., Guptha, S. et al. (2009) Effects of high-dose versus low-dose losartan on critical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet, 374, 1840-1848.
48. Carta, L., Smaldone, S., Zilberberg, L., Loch, D., Dietz, H.C., Rifkin, D.B. and Ramirez, F. (2009) p38 MAPK is an early determinant of promiscuous Smad2/3 signaling in the aortas of fibrillin-1 (Fbn1)-null mice. J. Biol. Chem., 284, 5630-5636.
49. Abe, M., Harpel, J.G., Metz, C.N., Nunes, I., Loskutoff, D.J. and Rifkin, D.B. (1994) An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem., 216, 276-284.
50. Zilberberg, L., ten Dijke, P., Sakai, L.Y. and Rifkin, D.B. (2007) A rapid and sensitive bioassay to measure bone morphogenetic protein activity. BMC Cell Biol., 8, 41.